Idiopathic Pulmonary Fibrosis - Applying New Options to Real World Cases
Two attendance options:
DMU faculty, staff, students, residents, and the medical community.
Lessons for Optimizing Treatment (PILOT) is a national education initiative designed to provide physicians with a comprehensive continuing medical education activity that focuses on the early and accurate diagnosis of IPF while also addressing critical issues related to optimizing disease intervention and management.
- Evaluate clinical trial data on available and emerging treatments for IPF and potential application to practice
- Explain the impact and treatment of common comorbidities of IPF
- Identify opportunities for referral as part of the multidisciplinary IPF management plan
Needs Assessment Sources
- Douglas WW, et al. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1172-1178.
- Flaherty KR, et al. Eur Respir J. 2002;19:275-283.
- Hubbard RB, et al. Am J Respir Crit Care Med. 2008;178:1257-1261.
- IPF Clinical Research Network, et al. N Engl J Med. 2012;366:1968-1977.
- Lancaster LH, et al. Chest. 2009;136:772-778.
- Lee JS, et al. Am J Respir Crit Care Med. 2011;184(12):1390-1394.
- Lettieri CJ, et al. Chest .2006. 129:746-752.
- Katz PO, et al. Am J Gastroenterol. 2013;108(3):308-328.
- King TE, et al. N Engl J Med. 2014;370(22):2083-2092.
- Martinez FJ, et al. N Engl J Med. 2014;370(22):2093-2101.
- Nagai S, et al. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):209-214.
- Nathan SD, et al. Chest. 2011;140(1):221-229.
- Nathan SD, et al. Respir Med. 2010:104:1035-1041.
- Olson AL. Am J Respir Crit Care Med. 2007;176(3):277-284.
- Raghu G, et al, and the ATS/ERS/JRS/ALAT Committee on IPF. Am J Respir Crit Care Med. 2011;183:788-824
- Raghu G, et al. Lancet Respir Med. 2014;2(7):566-572.
- Raghu G, et al; ATS, ERS, JRS, and ALAT. Am J Respir Crit Care Med. 2015;192(2):e3-e19.
- Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6):788-824.
- Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.
- Travis WD, et al, and the ATS/ERS Committee on IIPs. Am J Respir Crit Care Med. 2013;188(6):733-748.
- Washko GR, et al; Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011 Mar 10;364(10):897-906. doi: 10.1056/NEJMoa1007285
- Weill D, et al. J Heart Lung Transplant. 2015;34(1):1-15.
Mary Beth Scholand, MD is an assistant professor in Pulmonary Medicine from The University of Utah. Her research and clinical interest is Interstitial Lung Disease. This interest encompasses Idiopathic Pulmonary Fibrosis, Autoimmune Lung Diseases and Sarcoidosis. She is the Director of the Interstitial Lung Disease Clinic. She runs clinical trials focused on a cure for Idiopathic Pulmonary Fibrosis. In addition, her research focuses on phenotypic factors and genetic factors associated with Chronic Obstructive Pulmonary Diseases and Interstitial Lung Diseases.
Relevant to the content of this educational activity, the speaker indicated she is an investigator, advisory board member, and/or on the speakers bureau for Genentech, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead, Fibrogen, Afferent Pharmaceuticals, NIH.
Her presentation was reviewed by the DMU CME Director and Advisory Board Chair to ensure the content is balanced, fair, and does not represent a single commercial interest company.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University is accredited by the American Osteopathic Association (AOA) and approves this activity for 1.0 hour of Category 2-A CME credit(s).
- Other: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
No commercial interest provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2A
- 1.00 CE Contact Hour(s)